Appeals Rulings Signal Punishment is Easing for Big Tobacco

  5/26/2015 Perhaps no industry besides investment banks has been hit as hard by the federal court system than tobacco over the past several years. A pair of recent appeals rulings, however, indicates a substantial turn in the industry’s decades-long financial flogging. On Friday, the D.C. Court of Appeals delivered a mixed-ruling, in which some



SGLT2 Drugs Have Negative History with FDA

  5/21/2015 Quite surprising to me, I found that SGLT2 drugs have negative history with FDA. Not surprising, especially after finding the history, is the warning FDA released earlier this week. It appears that canagliflozin, sold as Invokana, may have created problems in the clinical trials that should have prevented its release. Just as other


SGLT2 Clinical Research and Side-Effects

5/19/2015 The Food and Drug Administration’s (FDA) May 15th warning of potential ketoacidosis among Type II diabetes patients who use a new class of oral treatments known as SGLT2 inhibitors should not be completely surprising. The first such medicine approved by the FDA in March, 2013 was Invokana (canagliflozin), manufactured by Janssen Pharmaceuticals in conjunction


Treatment Regimen for SGLT2-Related Ketoacidosis

5/19/2015 Yesterday we wrote about the warning issued by the FDA regarding SGLT2 type 2 diabetes medications. Today, I want to share the treatment regimen for SGLT2-related ketoacidosis. Always consult your physician before making changes in any medication protocol. If you find yourself experiencing any of the symptoms of ketoacidosis, get to the emergency room




TPP Turns Healthcare into Wealthcare

Image courtesy of LifeWorld 5/8/2015 Welcome to the Trans-Pacific Partnership agreement, hailed as the best piece of secret policy making since Moses’ conversation on a mountaintop. This week, I’m focusing on how the TPP turns healthcare into wealthcare. You should be afraid, very afraid. It’s profits before people (again!) with Big Pharma coming out the


Medtronic Plc Agrees to Consent Decree with the FDA

5/1/2015 Pending approval from U.S. district court in Minnesota, Medtronic Plc agrees to consent decree with the FDA regarding its SynchroMed implantable drug pump. The company will correct problems that cause the pumps to deliver either too little or too much medication. The pumps are used for treating cancer and chronic pain patients and those


FDA Issued Stop Distribution Letters to Companies Producing BMPEA-containing Supplements

4/29/2015 Pressure from various officials finally got the FDA to step in regarding beta-methylphenethylamine (BMPEA), a substance used in weight loss, energy boosting and pre-workout supplements. The FDA issued stop distribution letters to companies producing BMPEA-containing supplements. This is a move I can support, unlike many other FDA positions on non-Big Pharma products. Image: Wikipedia,